NRG-DT001: Amendment 4; Version Date: October 9, 2018

The protocol was amended to reflect new biomarker information for TP53-wild type tumor status.

Pending IRB approval of amendment 4, the study is reopen to accrual. Documentation of IRB approval of the amendment must be submitted to the CTSU Regulatory Office prior to enrolling participants. Expedited review is allowed at the discretion of the IRB Chair.

Documents are available on the NRG Oncology website and CIRB tab of the CTSU website.

 

 

 

 

 

 

Twitter
Facebook

Four Penn Center 1600 JFK Blvd. Suite1020 Philadelphia, PA, 19103


Update Profile/Email Address